Mammalian cell expression systems represent the gold standard for producing complex eukaryotic proteins that require correct folding, assembly, and authentic post-translational modifications (PTMs). Profacgen provides comprehensive mammalian cell expression services using industry-proven platforms, including HEK293 and CHO cell lines, to support the production of recombinant proteins and antibodies in their most native and biologically active forms. From rapid transient expression for research applications to stable cell line development and large-scale production, our services are designed to deliver high-quality proteins that meet the stringent requirements of functional studies, preclinical research, and therapeutic development.
Mammalian cell expression systems are uniquely capable of producing recombinant proteins that closely resemble their natural counterparts in structure, modification, and biological function. Unlike prokaryotic or lower eukaryotic systems, mammalian hosts provide the cellular machinery required for complex post-translational modifications such as N- and O-linked glycosylation, phosphorylation, acetylation, and correct disulfide bond formation. These features are critical for the activity, stability, and immunogenicity of many therapeutic and research proteins.
As a result, mammalian expression systems are widely used for the production of secreted and membrane proteins, monoclonal antibodies, cytokines, hormones, growth factors, and recombinant glycoproteins including vaccines and enzymes. They are also indispensable in applications where subtle differences in glycosylation or folding can significantly impact bioactivity or clinical performance.
Among available mammalian hosts, Human Embryonic Kidney 293 (HEK293) cells and Chinese Hamster Ovary (CHO) cells are the most extensively characterized and widely adopted. HEK293 cells are particularly well suited for transient expression due to their high transfection efficiency and ease of culture, making them ideal for rapid, customized protein production at the research stage. In contrast, CHO cells are the dominant platform for stable expression and large-scale manufacturing of FDA-approved therapeutic proteins and antibodies, owing to their genetic stability, adaptability to serum-free suspension culture, and regulatory acceptance.
Profacgen offers flexible, end-to-end mammalian protein expression services that are highly customizable and cost-efficient.
Transient Mammalian Expression (HEK293 and CHO)
- Rapid protein production for research and preclinical studies
- High transfection efficiency and fast turnaround times
- Suitable for functional assays, structural studies, and proof-of-concept evaluation
- Scalable from small exploratory batches to pilot-scale production
Stable Mammalian Cell Line Development (CHO-Focused)
- Generation of high-producing, genetically stable cell lines
- Clone screening and selection based on productivity and product quality
- Long-term reproducibility and consistency for extended studies
- Foundation for large-scale and industrial protein manufacturing
Secreted and Membrane Protein Expression
- Optimized signal peptide selection and secretion strategies
- Expression of multi-domain and membrane-associated proteins
- Compatible with downstream purification and functional characterization
Monoclonal Antibody Expression
- Full-length IgG and antibody fragment production
- Optimized expression and purification workflows
- Suitable for binding, functional, and preclinical evaluation
Core fucosylation of N-linked glycans plays a critical role in modulating antibody effector functions, particularly antibody-dependent cellular cytotoxicity (ADCC). The enzyme α-1,6-fucosyltransferase (FUT8) is responsible for adding core fucose to IgG Fc glycans in mammalian cells. FUT8-knockout CHO K1 cell lines lack this enzymatic activity, enabling the production of afucosylated antibodies with significantly enhanced ADCC activity.
Profacgen offers specialized protein and antibody expression services using Fut8-CHO K1 cell lines. This platform enables the production of recombinant antibodies and Fc-containing proteins with controlled and reduced core fucosylation, making it highly valuable for antibody engineering, functional studies, and early-stage therapeutic development.
Key Applications
→ Learn More: Fut8-CHO K1 Cell Protein and Antibody Expression Service
Background
The client required rapid production of a human recombinant cytokine for cell-based functional assays and receptor binding studies. Key requirements included correct folding, efficient secretion, and preservation of biological activity. Timeline pressure ruled out stable cell line development, while alternative systems failed to reproduce native activity.
Our Solution
Profacgen implemented a transient HEK293 expression strategy using a secretion-optimized construct and codon-optimized gene. Transfection conditions, culture media, and harvest timing were optimized to maximize yield and bioactivity. Affinity-based purification was performed under mild conditions to preserve protein integrity.
Final Results
The cytokine was delivered within a short turnaround time at high purity and demonstrated robust, dose-dependent biological activity in functional assays, enabling the client to advance their research program without delay.
Background
The client required long-term, reproducible production of a complex therapeutic glycoprotein for extended preclinical evaluation. Consistent expression levels, defined glycosylation patterns, and batch-to-batch reproducibility were critical, as the protein was intended for repeated in vivo studies.
Our Solution
A stable CHO expression strategy was selected. Profacgen performed codon optimization, stable transfection, and extensive clone screening to identify high-producing, genetically stable clones. Culture conditions and feeding strategies were optimized, and a scalable purification process was established.
Final Results
The resulting CHO cell line delivered consistent protein yields with reproducible glycosylation profiles and preserved biological activity, supporting the client's long-term preclinical and formulation studies.
Background
The client aimed to enhance the antibody-dependent cellular cytotoxicity (ADCC) of a monoclonal antibody candidate while maintaining overall antibody structure and stability. Controlled reduction of Fc core fucosylation was required to support structure–function studies and early-stage therapeutic evaluation.
Our Solution
Profacgen expressed the antibody in Fut8-CHO K1 cells, which lack α-1,6-fucosyltransferase activity. Expression conditions were optimized to ensure robust antibody yield, followed by purification and detailed glycan analysis to confirm afucosylation levels.
Final Results
The resulting antibody demonstrated significantly enhanced ADCC activity compared to conventionally produced material, validating the Fut8-CHO K1 platform as an effective tool for antibody glycoengineering and potency optimization.
Consult Our Experts on Your Project
With extensive experience in mammalian cell expression, Profacgen delivers high-quality recombinant proteins and antibodies through robust platforms and customized strategies. Contact us to discuss how our mammalian expression services can support your research and development goals.
Fill out this form and one of our experts will respond to you within one business day.